Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Operations (2018 - 2025)

UroGen Pharma (URGN) has disclosed Cash from Operations for 8 consecutive years, with 38325000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 181.41% year-over-year to 38325000.0, compared with a TTM value of 162444000.0 through Dec 2025, down 67.87%, and an annual FY2025 reading of 162444000.0, down 67.87% over the prior year.
  • Cash from Operations was 38325000.0 for Q4 2025 at UroGen Pharma, up from 42270000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12996000.0 in Q4 2023 and bottomed at 42270000.0 in Q3 2025.
  • Average Cash from Operations over 5 years is 25401850.0, with a median of 23872000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 40.25% in 2023, then plummeted 181.41% in 2025.
  • Year by year, Cash from Operations stood at 20070000.0 in 2021, then fell by 8.38% to 21752000.0 in 2022, then surged by 40.25% to 12996000.0 in 2023, then decreased by 4.79% to 13619000.0 in 2024, then tumbled by 181.41% to 38325000.0 in 2025.
  • Business Quant data shows Cash from Operations for URGN at 38325000.0 in Q4 2025, 42270000.0 in Q3 2025, and 39825000.0 in Q2 2025.